Immunotherapy in Renal Cell Carcinoma.

Area of Science:

• Oncology
• Immunology

Background:

• Immunotherapy has revolutionized renal cell carcinoma (RCC) treatment, evolving from early cytokine-based therapies to current immune checkpoint inhibitor (ICI) combinations.
• ICI-based therapies have significantly improved patient outcomes in RCC, providing durable responses for a portion of the patient population.

Purpose of the Study:

• To review key frontline ICI-based combinations for metastatic RCC.
• To discuss recent advancements in adjuvant immunotherapy and immunotherapy rechallenge after prior ICI exposure.
• To explore emerging immunotherapy strategies, including chimeric antigen receptor (CAR) T-cell therapy and gut microbiome interventions.

Main Methods:

• Review of clinical trial data for frontline ICI combinations in metastatic RCC.
• Analysis of recent studies on adjuvant immunotherapy and treatment rechallenge.
• Exploration of novel immunotherapy strategies and their potential application in RCC.

Main Results:

• ICI-based combinations have demonstrated significant efficacy in the first-line metastatic RCC setting.
• Adjuvant immunotherapy and rechallenge strategies show promise for improving long-term outcomes.
• Emerging therapies like CAR T-cell therapy and microbiome interventions represent future directions in RCC immunotherapy.

Conclusions:

• Current immunotherapy approaches, particularly ICI combinations, have markedly improved outcomes for patients with advanced RCC.
• Future directions include optimizing adjuvant and rechallenge strategies, alongside novel immunotherapeutic modalities.
• A multidisciplinary approach is crucial for managing immune-related adverse events and integrating cytoreductive nephrectomy in the evolving RCC treatment landscape.